Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Boundless Bio, Inc.BOLD · Entity 7063 | Chief Scientific Officer | January 23, 2026 | January 26, 2026 |
| Sierra Oncology, Inc.SRRA · Entity 125698 | Chief Scientific Officer | March 04, 2019 | March 05, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Boundless Bio, Inc.
Report date January 23, 2026 · Filed January 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.26 · Expires 2036-01-22 | Direct | 230,000 |
Reported balance
After 2026-01-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-23 · Grant · Acquired 230,000 · Balance 230,000 F1: The vesting commencement date is January 1, 2026. The stock option vests in 48 substantially equal monthly installments. Accordingly, 1/48th of this stock option vests on February 1, 2026, and monthly thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: The vesting commencement date is January 1, 2026. The stock option vests in 48 substantially equal monthly installments. Accordingly, 1/48th of this stock option vests on February 1, 2026, and monthly thereafter.
Sierra Oncology, Inc.
Report date March 04, 2019 · Filed March 05, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.96 · Expires 2029-03-04 | Direct | 155,000 |
Reported balance
After 2019-03-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-03-04 · Grant · Acquired 155,000 · Balance 155,000 F1: The option vests as to 25% of the total shares on January 1, 2020, and then 2.0833% of the total shares vest monthly thereafter, with 100% of the total shares vested on January 1, 2023, subject to the reporting person's provision of service to the issuer on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests as to 25% of the total shares on January 1, 2020, and then 2.0833% of the total shares vest monthly thereafter, with 100% of the total shares vested on January 1, 2023, subject to the reporting person's provision of service to the issuer on each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 23, 2026 Filed Jan 26, 2026 07:00 UTC | Boundless Bio, Inc. BOLD · Entity 7063 | GrantStock Option (right to buy) · Derivative | 230,000 | $0.00 Strike: $1.26 | $0.00 |
DisclosureSEC source: 0001193125-26-021657 · ownership.xml · derivative · entry 1 Hassig Christian · CIK 0001730657 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 230,000 Underlying: Common Stock · 230,000 shares Expires 2036-01-22 F1 · derivative.exercise_date: The vesting commencement date is January 1, 2026. The stock option vests in 48 substantially equal monthly installments. Accordingly, 1/48th of this stock option vests on February 1, 2026, and monthly thereafter. Read SEC document |
| January 22, 2025 Filed Jan 23, 2025 16:05 UTC | Boundless Bio, Inc. BOLD · Entity 7063 | GrantStock Option · Derivative | 95,000 | $0.00 Strike: $2.57 | $0.00 |
DisclosureSEC source: 0000950170-25-008319 · ownership.xml · derivative · entry 1 Hassig Christian · CIK 0001730657 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 95,000 Underlying: Common Stock · 95,000 shares Expires 2035-01-21 F1 · derivative.exercise_date: The stock option vests in 48 substantially equal monthly installments beginning on February 1, 2025. Read SEC document |
| August 19, 2024 Filed Aug 20, 2024 19:11 UTC | Boundless Bio, Inc. BOLD · Entity 7063 | GrantStock Option · Derivative | 48,703 | Not disclosed Strike: $3.56 | Not disclosed |
DisclosureSEC source: 0000950170-24-099308 · ownership.xml · derivative · entry 10 Hassig Christian · CIK 0001730657 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,703 Underlying: Common Stock · 48,703 shares Expires 2034-03-26 F7 · derivative.exercise_price: The exercise price of the option is $3.56 per share, representing the fair market value per share of the common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the "premium end date" (as defined below), the repriced option is exercised or the reporting person's employment is terminated for any reason other than a "qualifying termination" (as defined below). The "premium end date" means the earliest of: (i) August 19, 2026, (ii) the date immediately prior to the closing of a change in control, or (iii) the date of the employee's qualifying termination. A "qualifying termination" means (a) the involuntary termination of the employee's employment by the Company due to a reduction in force (and other than for cause), or (b) the employee's termination due to death or disability. F2 · price: On August 19, 2024, the Issuer repriced the option. Except as described further in footnote 7, all other terms of the option remain unchanged. F6 · derivative.exercise_date: The stock option vests in 48 substantially equal monthly installments beginning on April 27, 2024. Read SEC document |
| August 19, 2024 Filed Aug 20, 2024 19:11 UTC | Boundless Bio, Inc. BOLD · Entity 7063 | GrantStock Option · Derivative | 76,173 | Not disclosed Strike: $3.56 | Not disclosed |
DisclosureSEC source: 0000950170-24-099308 · ownership.xml · derivative · entry 9 Hassig Christian · CIK 0001730657 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 76,173 Underlying: Common Stock · 76,173 shares Expires 2034-02-14 F7 · derivative.exercise_price: The exercise price of the option is $3.56 per share, representing the fair market value per share of the common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the "premium end date" (as defined below), the repriced option is exercised or the reporting person's employment is terminated for any reason other than a "qualifying termination" (as defined below). The "premium end date" means the earliest of: (i) August 19, 2026, (ii) the date immediately prior to the closing of a change in control, or (iii) the date of the employee's qualifying termination. A "qualifying termination" means (a) the involuntary termination of the employee's employment by the Company due to a reduction in force (and other than for cause), or (b) the employee's termination due to death or disability. F2 · price: On August 19, 2024, the Issuer repriced the option. Except as described further in footnote 7, all other terms of the option remain unchanged. F5 · derivative.exercise_date: The stock option vests in 48 substantially equal monthly installments beginning on March 15, 2024. Read SEC document |
| August 19, 2024 Filed Aug 20, 2024 19:11 UTC | Boundless Bio, Inc. BOLD · Entity 7063 | GrantStock Option · Derivative | 94,871 | Not disclosed Strike: $3.56 | Not disclosed |
DisclosureSEC source: 0000950170-24-099308 · ownership.xml · derivative · entry 8 Hassig Christian · CIK 0001730657 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 94,871 Underlying: Common Stock · 94,871 shares Expires 2033-06-12 F7 · derivative.exercise_price: The exercise price of the option is $3.56 per share, representing the fair market value per share of the common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the "premium end date" (as defined below), the repriced option is exercised or the reporting person's employment is terminated for any reason other than a "qualifying termination" (as defined below). The "premium end date" means the earliest of: (i) August 19, 2026, (ii) the date immediately prior to the closing of a change in control, or (iii) the date of the employee's qualifying termination. A "qualifying termination" means (a) the involuntary termination of the employee's employment by the Company due to a reduction in force (and other than for cause), or (b) the employee's termination due to death or disability. F2 · price: On August 19, 2024, the Issuer repriced the option. Except as described further in footnote 7, all other terms of the option remain unchanged. F4 · derivative.exercise_date: The stock option vests in 48 substantially equal monthly installments beginning on July 13, 2023. Read SEC document |
| August 19, 2024 Filed Aug 20, 2024 19:11 UTC | Boundless Bio, Inc. BOLD · Entity 7063 | GrantStock Option · Derivative | 62,820 | Not disclosed Strike: $3.56 | Not disclosed |
DisclosureSEC source: 0000950170-24-099308 · ownership.xml · derivative · entry 7 Hassig Christian · CIK 0001730657 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,820 Underlying: Common Stock · 62,820 shares Expires 2031-06-06 F7 · derivative.exercise_price: The exercise price of the option is $3.56 per share, representing the fair market value per share of the common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the "premium end date" (as defined below), the repriced option is exercised or the reporting person's employment is terminated for any reason other than a "qualifying termination" (as defined below). The "premium end date" means the earliest of: (i) August 19, 2026, (ii) the date immediately prior to the closing of a change in control, or (iii) the date of the employee's qualifying termination. A "qualifying termination" means (a) the involuntary termination of the employee's employment by the Company due to a reduction in force (and other than for cause), or (b) the employee's termination due to death or disability. F2 · price: On August 19, 2024, the Issuer repriced the option. Except as described further in footnote 7, all other terms of the option remain unchanged. F3 · derivative.exercise_date: The stock option vests in 48 substantially equal monthly installments beginning on July 7, 2021. Read SEC document |
| August 19, 2024 Filed Aug 20, 2024 19:11 UTC | Boundless Bio, Inc. BOLD · Entity 7063 | GrantStock Option · Derivative | 10,256 | Not disclosed Strike: $3.56 | Not disclosed |
DisclosureSEC source: 0000950170-24-099308 · ownership.xml · derivative · entry 6 Hassig Christian · CIK 0001730657 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,256 Underlying: Common Stock · 10,256 shares Expires 2030-12-01 F7 · derivative.exercise_price: The exercise price of the option is $3.56 per share, representing the fair market value per share of the common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the "premium end date" (as defined below), the repriced option is exercised or the reporting person's employment is terminated for any reason other than a "qualifying termination" (as defined below). The "premium end date" means the earliest of: (i) August 19, 2026, (ii) the date immediately prior to the closing of a change in control, or (iii) the date of the employee's qualifying termination. A "qualifying termination" means (a) the involuntary termination of the employee's employment by the Company due to a reduction in force (and other than for cause), or (b) the employee's termination due to death or disability. F2 · price: On August 19, 2024, the Issuer repriced the option. Except as described further in footnote 7, all other terms of the option remain unchanged. F1 · derivative.exercise_date: The stock option vested as to 25% of the underlying shares on January 1, 2022, and vests as to the remaining underlying shares in 36 substantially equal monthly installments thereafter. Read SEC document |
| August 19, 2024 Filed Aug 20, 2024 19:11 UTC | Boundless Bio, Inc. BOLD · Entity 7063 | Disposition to issuerStock Option · Derivative | 48,703 | Not disclosed Strike: $16.00 | Not disclosed |
DisclosureSEC source: 0000950170-24-099308 · ownership.xml · derivative · entry 5 Hassig Christian · CIK 0001730657 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 48,703 shares Expires 2034-03-26 F2 · price: On August 19, 2024, the Issuer repriced the option. Except as described further in footnote 7, all other terms of the option remain unchanged. F6 · derivative.exercise_date: The stock option vests in 48 substantially equal monthly installments beginning on April 27, 2024. Read SEC document |
| August 19, 2024 Filed Aug 20, 2024 19:11 UTC | Boundless Bio, Inc. BOLD · Entity 7063 | Disposition to issuerStock Option · Derivative | 76,173 | Not disclosed Strike: $8.19 | Not disclosed |
DisclosureSEC source: 0000950170-24-099308 · ownership.xml · derivative · entry 4 Hassig Christian · CIK 0001730657 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 76,173 shares Expires 2034-02-14 F2 · price: On August 19, 2024, the Issuer repriced the option. Except as described further in footnote 7, all other terms of the option remain unchanged. F5 · derivative.exercise_date: The stock option vests in 48 substantially equal monthly installments beginning on March 15, 2024. Read SEC document |
| August 19, 2024 Filed Aug 20, 2024 19:11 UTC | Boundless Bio, Inc. BOLD · Entity 7063 | Disposition to issuerStock Option · Derivative | 94,871 | Not disclosed Strike: $4.10 | Not disclosed |
DisclosureSEC source: 0000950170-24-099308 · ownership.xml · derivative · entry 3 Hassig Christian · CIK 0001730657 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 94,871 shares Expires 2033-06-12 F2 · price: On August 19, 2024, the Issuer repriced the option. Except as described further in footnote 7, all other terms of the option remain unchanged. F4 · derivative.exercise_date: The stock option vests in 48 substantially equal monthly installments beginning on July 13, 2023. Read SEC document |
| August 19, 2024 Filed Aug 20, 2024 19:11 UTC | Boundless Bio, Inc. BOLD · Entity 7063 | Disposition to issuerStock Option · Derivative | 62,820 | Not disclosed Strike: $4.10 | Not disclosed |
DisclosureSEC source: 0000950170-24-099308 · ownership.xml · derivative · entry 2 Hassig Christian · CIK 0001730657 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 62,820 shares Expires 2031-06-06 F2 · price: On August 19, 2024, the Issuer repriced the option. Except as described further in footnote 7, all other terms of the option remain unchanged. F3 · derivative.exercise_date: The stock option vests in 48 substantially equal monthly installments beginning on July 7, 2021. Read SEC document |
| August 19, 2024 Filed Aug 20, 2024 19:11 UTC | Boundless Bio, Inc. BOLD · Entity 7063 | Disposition to issuerStock Option · Derivative | 10,256 | Not disclosed Strike: $3.71 | Not disclosed |
DisclosureSEC source: 0000950170-24-099308 · ownership.xml · derivative · entry 1 Hassig Christian · CIK 0001730657 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,256 shares Expires 2030-12-01 F2 · price: On August 19, 2024, the Issuer repriced the option. Except as described further in footnote 7, all other terms of the option remain unchanged. F1 · derivative.exercise_date: The stock option vested as to 25% of the underlying shares on January 1, 2022, and vests as to the remaining underlying shares in 36 substantially equal monthly installments thereafter. Read SEC document |
| March 27, 2024 Filed Mar 29, 2024 16:30 UTC | Boundless Bio, Inc. BOLD · Entity 7063 | GrantStock Option · Derivative | 48,703 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0000950170-24-038692 · ownership.xml · derivative · entry 1 Hassig Christian · CIK 0001730657 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,703 Underlying: Common Stock · 48,703 shares Expires 2034-03-26 F1 · derivative.exercise_date: The stock option vests in 48 substantially equal monthly installments beginning on April 27, 2024. Read SEC document |
| March 04, 2019 Filed Mar 5, 2019 17:27 UTC | Sierra Oncology, Inc. SRRA · Entity 125698 | GrantStock Option (right to buy) · Derivative | 155,000 | $0.00 Strike: $1.96 | $0.00 |
DisclosureSEC source: 0001209191-19-016738 · doc4.xml · derivative · entry 1 Hassig Christian · CIK 0001730657 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,000 Underlying: Common Stock · 155,000 shares Expires 2029-03-04 F1 · derivative.exercise_date: The option vests as to 25% of the total shares on January 1, 2020, and then 2.0833% of the total shares vest monthly thereafter, with 100% of the total shares vested on January 1, 2023, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| March 06, 2018 Filed Mar 7, 2018 17:54 UTC | Sierra Oncology, Inc. SRRA · Entity 125698 | GrantStock Option (right to buy) · Derivative | 205,180 | $0.00 Strike: $2.36 | $0.00 |
DisclosureSEC source: 0001209191-18-017778 · doc4.xml · derivative · entry 1 Hassig Christian · CIK 0001730657 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 205,180 Underlying: Common Stock · 205,180 shares Expires 2028-03-06 F1 · derivative.exercise_date: The option vests as to 25% of the total shares on January 1, 2019, and then 2.0833% of the total shares vest monthly thereafter, with 100% of the total shares vested on January 1, 2022, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.